Lantern Pharma is trading 10.4% down at $1.81 in pre-market, with no clear company-specific announcement identified for September 2, 2026; the reason remains unconfirmed.
- Recent available company coverage centers on its August 14, 2026 earnings and earlier financing, rather than a new overnight catalyst.
- Nasdaq futures are down 0.16%, reflecting mildly defensive sentiment, but the move is too limited to clearly explain the decline.